Europital launches as a science-driven full-service CRO
Expanded CRO services to support biotechs and mid-sized pharma companies across trials in more than 40 countries.
Europital, a globally focused full-service CRO serving small and mid-tier innovators, has launched new capabilities across project management, clinical monitoring, biostatistics, pharmacovigilance, regulatory affairs and data management, in addition to its existing medical affairs and medical writing services.
The expanded clinical research offering will see Europital support clients in more than 40 countries from investigational new drug (IND) through to commercial launch.
Dr Mohamed El Malt, Chief Medical Officer of Europita, said: “It’s no secret, there is a large gap in the CRO industry for these small innovators; what they need is a science-driven CRO that will support them closely with an experienced senior team but combined with a global trial network."
Europital has regional offices in Belgium, Hungary and the UK, with customers based in Europe and the US. Innovators developing therapies for oncology, infectious diseases, inflammatory and autoimmune diseases will be the major beneficiaries of the company's multifunctional and operational capabilities.
Sponsors who will particularly benefit are those that require a full range of CRO services for complex molecules and trial designs that necessitate senior medical and scientific oversight.
In addition to its regional offices in Europe, Europital has built a global network of trusted partners during the last 10 years with local operational expertise and preferential supply trial site agreements in the US, Canada, Russia, India, the Middle East and North Africa and Australia.
Dr El Malt explained that the decision to launch as a full-service CRO reflects the many requests it received from its clients to work on additional aspects of their clinical trials, the services for which they did not have in-house. Now, with the expansion, the company can provide a 360-degree CRO service to innovators in the pharmaceutical, biotechnology and medical devices sectors.
Related News
-
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc... -
News Key takeaways from Saudi Arabia's National Biotechnology Strategy
In January 2024, Saudi Arabia released its National Biotech Strategy, an ambitious plan to localise biomanufacturing, incentivise R&D and establish the Kingdom as the regional biotech leader by 2030, and an internationally recognised hub by 2040. -
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance